Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prednisone is a synthetic glucocorticoid corticosteroid used primarily for its anti-inflammatory and immunosuppressive properties. It is indicated for the treatment of a wide range of conditions including autoimmune diseases (such as rheumatoid arthritis and lupus), severe allergic reactions, asthma and other respiratory disorders (like COPD), inflammatory bowel diseases (ulcerative colitis and Crohn’s disease), certain cancers (notably hematologic malignancies), adrenal insufficiency when endogenous corticosteroid production is inadequate or absent, skin disorders, blood disorders and more[1][2][3][5][6]. Prednisone acts as a prodrug that is converted in the liver to prednisolone—its active form—which binds to glucocorticoid receptors. This binding alters gene expression in target cells to suppress inflammation by inhibiting proinflammatory cytokine production and immune cell migration. It also induces apoptosis in certain tumor cell populations[5][6]. Prednisone was patented in 1954 and approved for medical use in 1955; it remains widely prescribed globally[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prednisone.